Literature DB >> 9760067

Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.

M Trepel1, P Groscurth, U Malipiero, E Gulbins, J Dichgans, M Weller.   

Abstract

Loss of wild-type p53 activity is one of the most common molecular abnormalities in human cancers including malignant gliomas. The p53 status is also thought to modulate sensitivity to irradiation and chemotherapy. Here, we studied the effect of a p53 gene transfer on the chemosensitivity of three human glioma cell lines with different endogenous p53 status (LN-229, wild-type; LN-18, mutant; LN-308, deleted), using the murine temperature-sensitive p53 val135 mutant. Expression of mutant p53 enhanced proliferation of LN-308 cells but reduced proliferation in the other cell lines. Expression of wild-type p53 caused reversible growth arrest of all cell lines but failed to induce apoptosis. Growth arrest induced by wild-type p53 was associated with strong induction of p21 expression. Strong induction of BAX expression and loss of BCL-2 expression, which are associated with p53-dependent apoptosis rather than growth arrest, were not observed. Wild-type p53 failed to sensitize glioma cells to cytotoxic drugs including BCNU, cytarabine, doxorubicin, teniposide and vincristine. The combined effects of wild-type p53 gene transfer and drug treatment were less than additive rather than synergistic, suggesting that the intracellular cascades activated by p53 and chemotherapy are redundant. Unexpectedly, forced expression of mutant p53 modulated drug sensitivity in that it enhanced the toxicity of some drugs but attenuated the effects of others. These effects may represent a dominant negative effect of mutant p53 in LN-229 cells which have wild-type p53 activity but must be considered a gain of function-type effect in the other two cell lines which have no wild-type p53 activity. Importantly, no clear-cut pattern emerged among the three cell lines studied. We conclude that somatic gene therapy based on the reintroduction of p53 will limit the proliferation of human malignant glioma cells but is unlikely to induce clinically relevant sensitization to chemotherapy in these tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9760067     DOI: 10.1023/a:1005910323338

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  57 in total

1.  Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.

Authors:  M Weller; M Trepel; C Grimmel; M Schabet; D Bremen; S Krajewski; J C Reed
Journal:  Neurol Res       Date:  1997-10       Impact factor: 2.448

Review 2.  P53 and induction of apoptosis as a target for anticancer therapy.

Authors:  A Neubauer; C Thiede; D Huhn; B Wittig
Journal:  Leukemia       Date:  1996-07       Impact factor: 11.528

3.  Identification of a p53-dependent negative response element in the bcl-2 gene.

Authors:  T Miyashita; M Harigai; M Hanada; J C Reed
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

4.  Wild-type p53 regulates its own transcription in a cell-type specific manner.

Authors:  J M Hudson; R Frade; M Bar-Eli
Journal:  DNA Cell Biol       Date:  1995-09       Impact factor: 3.311

5.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.

Authors:  W E Mercer; M T Shields; M Amin; G J Sauve; E Appella; J W Romano; S J Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.

Authors:  D G Brachman; M Beckett; D Graves; D Haraf; E Vokes; R R Weichselbaum
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

Review 7.  Tumor suppressor p53 mutations and breast cancer: a critical analysis.

Authors:  M A Ozbun; J S Butel
Journal:  Adv Cancer Res       Date:  1995       Impact factor: 6.242

8.  p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors.

Authors:  S J Russell; Y W Ye; P G Waber; M Shuford; S C Schold; P D Nisen
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860

9.  p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.

Authors:  D J van Meyel; D A Ramsay; A G Casson; M Keeney; A F Chambers; J G Cairncross
Journal:  J Natl Cancer Inst       Date:  1994-07-06       Impact factor: 13.506

10.  Negative feedback regulation of wild-type p53 biosynthesis.

Authors:  J Mosner; T Mummenbrauer; C Bauer; G Sczakiel; F Grosse; W Deppert
Journal:  EMBO J       Date:  1995-09-15       Impact factor: 11.598

View more
  10 in total

1.  Modulation of MDR/MRP by wild-type and mutant p53.

Authors:  O Bähr; W Wick; M Weller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.

Authors:  J Ikeda; M Tada; N Ishii; H Saya; K Tsuchiya; K Okaichi; K Mishima; Y Sawamura; G Fulci; T J Liu; E G Van Meir
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

3.  Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.

Authors:  M H Deininger; E Grote; J Wickboldt; R Meyermann
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

4.  Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity.

Authors:  T Glaser; S Winter; P Groscurth; H Safayhi; E R Sailer; H P Ammon; M Schabet; M Weller
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.

Authors:  Dovilė Kavaliauskaitė; Donatas Stakišaitis; Justė Martinkutė; Lina Šlekienė; Arūnas Kazlauskas; Ingrida Balnytė; Vaiva Lesauskaitė; Angelija Valančiūtė
Journal:  Biomed Res Int       Date:  2017-05-31       Impact factor: 3.411

6.  The Anti-Cancer Effect of Four Curcumin Analogues on Human Glioma Cells.

Authors:  Siou-Min Luo; Yi-Ping Wu; Li-Chun Huang; Shih-Ming Huang; Dueng-Yuan Hueng
Journal:  Onco Targets Ther       Date:  2021-08-04       Impact factor: 4.147

7.  Tetrandrine Suppresses Human Brain Glioblastoma GBM 8401/luc2 Cell-Xenografted Subcutaneous Tumors in Nude Mice In Vivo.

Authors:  Ching-Lung Liao; Yi-Shih Ma; Te-Chun Hsia; Yu-Cheng Chou; Jin-Cherng Lien; Shu-Fen Peng; Chao-Lin Kuo; Fei-Ting Hsu
Journal:  Molecules       Date:  2021-11-24       Impact factor: 4.411

Review 8.  Non-cytotoxic therapies for malignant gliomas.

Authors:  Umberto Basso; Mario Ermani; Francesca Vastola; Alba A Brandes
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.506

Review 9.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

10.  Synthetic Cannabinoids Influence the Invasion of Glioblastoma Cell Lines in a Cell- and Receptor-Dependent Manner.

Authors:  Tim Hohmann; Kerstin Feese; Thomas Greither; Chalid Ghadban; Vivian Jäger; Faramarz Dehghani; Urszula Grabiec
Journal:  Cancers (Basel)       Date:  2019-01-31       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.